N/A N=180 MINDSpeed Food and Brain Training RCT
Low Education · Cognition · Cognitive Training
Primary: Executive Cognitive Function Composite Score — 0.211; 0.100; 0.142; 0.196 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Transcranial Direct Current Stimulation (tDCS)
Brain Fog
Primary: Perceived Ease of Use After 4 Weeks of Daily tDCS Use (TAM Score) — 30.5 units on a scale
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
N/A N=301 Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy
Medication Adherence
Primary: Medication Specific Knowledge — 63.82; 62.80 score (0-100)
N/A N=30 Evaluation of a New 6 Minute Walk Test Smartphone App in Patients With Pulmonary Hypertension
Pulmonary Hypertension
Primary: Percentage of Participants Who Perform App-based Home 6MWT — 30 Participants
Phase 1 N=22 First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE)…
Phase 2 N=13 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
NSCLC · Metastatic Colorectal Carcinoma · Refractory Melanoma
Primary: Objective Response Rate (ORR) — 40; 37.5; 60; 62.5 percentage of patients — p=1.0000
N/A N=62 Examining Brain Responses Linked to Emotion in Individuals Who Smoke Cigarettes
Smoking, Tobacco
Primary: Brain Activation During Smoking-related and Neutral Cues — 5.8; -1.6; 1.1; -4.2 contrast of parameter estimate — p=0.13
Phase 1 N=48 Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19
SARS-CoV-2
Primary: The Number of Participants With Serious Adverse Events Following Administration of ADM03820 to the Final Visit — 1; 1; 0; 0 Participants
Phase 3 N=429 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Giant Cell Arteritis (GCA)
Primary: Percentage of Participants Achieving Sustained Remission at Week 52 — 29.0; 41.1; 46.4 percentage of participants — p==0.0019
N/A N=200 The Effect of the Feldenkrais Method on Pain and Function in Patients With Chronic Neck Pain
Neck Pain
Primary: Pain Pressure Threshold Measured by the Commander Algometer, JTECH Medical, Midvale, Utah. — 1.24; 1.32; 1.61; 1.34 kg/cm^2 — p==0.002
N/A N=10 Application of a Reimbursable Form of Constraint-Induced Movement Therapy for Upper Extremity
CVA (Cerebrovascular Accident) · Stroke · Upper Extremity Paresis
Primary: Motor Activity Log (MAL) — 1; 1.1 Points
N/A N=64 Enhancing Social Competence in Adults With Autism
Autism Spectrum Disorder
Primary: Change in Incidental Face Memory — 0.6588; -0.1604; 0.469; -0.77 microvolts — p=0.016
Phase 2 N=91 Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Percentage of Participants With at Least 1-Level Lower Score 3 to 5 Days After Initial CCH-aaes Injection, as Assessed by the Investigator Assessment of Bruising…
N/A N=50 Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics
Tic Disorders · Tics · Tic, Motor
Primary: Change in Resting State fMRI Connectivity of SMA-mediated Brain Circuits — 0.0312; 0.261; 0.158 eta squared